1 active not recruiting, 1 completed, 1 not yet recruiting, 1 recruiting. 2 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD): new trials by email Literature Review of Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) trials Research Report on Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Linzhi Jianghuang Fufang Huoxue Anshen Capsule for Non-alcoholic Fatty Liver Linzhi Jianghuang Fufang Huoxue Anshen Capsule (LJF), Placebo - Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | Phase 2 | Not yet recruiting | Hong Kong Baptist University | 180 | 2026-09-01 | 2026-06-09 |
| Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine - Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly | Not applicable | Recruiting | Phenomen Pharma | 90 | 2025-06-19 | 2025-07-23 |
| A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD） IBI362, semaglutide - Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | Phase 3 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 479 | 2025-05-09 | 2026-05-12 |
| Adiponectin in Patients With Metabolic Disorders SGLT2 inhibitor, GLP-1 RA - Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Type 2 Diabetes Mellitus (T2DM) | Not applicable | Completed | Moscow Regional Research and Clinical Institute (MONIKI) | 130 | 2022-03-01 | 2026-04-22 |
Non-alcoholic Fatty Liver Disease (2) · Diabetes Mellitus, Type 2 (1) · Fatty Liver (1) · Fatty Liver, Alcoholic (1) · Hepatomegaly (1) · Liver Diseases (1) · Overweight (1)
Digestive System Diseases (2) · Nutritional and Metabolic Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Alcohol-Induced Disorders (1) · Alcohol-Related Disorders (1) · Body Weight (1) · Chemically-Induced Disorders (1) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Fatty Liver (1) · Glucose Metabolism Disorders (1) · Hypertrophy (1) · Liver Diseases (1) · Liver Diseases, Alcoholic (1) · Metabolic Diseases (1)
S-Adenosylmethionine (1) · Sodium-Glucose Transporter 2 Inhibitors (1) · Ursodeoxycholic Acid (1) · mazdutide (1) · semaglutide (1)
Hong Kong Baptist University (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Moscow Regional Research and Clinical Institute (MONIKI) (1) · Phenomen Pharma (1)
Russia (2) · China (1)
Lixin Guo, M.D (1)